Clinical trials: Treatment Resistant Schizophrenia
Schizophrenia
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
In this study, the investigators will investigate the impact and the related mechanism of metformin treatment on cognitive impairment of schizophrenia with a high risk of metabolic syndrome.
- Trial name
- NCT03271866
- Testing
- metformin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Central South University
Schizophrenia
Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia
Auditory Hallucinations (AH) are experienced by 50 to 70% of subjects with schizophrenia. Almost a quarter of patients are medication resistant to such symptoms.
- Trial name
- rTMS (NCT02175251)
- Testing
- high frequency (20Hz), low frequency (1Hz)
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Treatment-resistant Schizophrenia
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS)
- Trial name
- Anew (NCT03230864)
- Testing
- Lu AF35700, Risperidone, Olanzapine
- Where
- 41 sites in United States, Bulgaria and 3 more
- Volunteers
- 119 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia. Is it effective and efficacious?
- Trial name
- ATHSCHIZ (NCT05623228)
- Testing
- The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia
- Where
- Greece
- Volunteers
- 35 people
- Sponsor
- Rakitzi, Stavroula
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Schizophrenia, Transcranial Magnetic Stimulation
Evaluation of the Efficacy of Transcranial Magnetic Stimulation on Resistant Auditory Hallucinations in Schizophrenia
This open naturalistic study aims to evaluate the efficacy of rTMS in routine practice on auditory resistant hallucinations (AHR) of patients with schizophrenia.
- Conditions
- Schizophrenia, Transcranial Magnetic Stimulation, Hallucinations, Verbal Auditory
- Trial name
- HRRENAT (NCT06599372)
- Testing
- The rTMS method, The cTBS method
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Dominique JANUEL
Auditory Hallucination, Verbal, Treatment-resistant Schizophrenia
Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory Hallucinations
Schizophrenia is associated with long-lasting health, social and financial burden for patients, families, caregivers and society.
- Trial name
- Phase3 (NCT04054778)
- Testing
- Avatar Therapy, Cognitive Behavioral Therapy
- Where
- Canada
- Volunteers
- 136 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Clozapine Resistant Schizophrenia
Vitamin D for Schizophrenia
Background: Despite improvements in medications, treatment delivery and rehabilitation, schizophrenia outcomes remain suboptimal. There are a proportion of 30-40% treatment-resistant schizophrenia patients.
- Trial name
- NCT01759485
- Testing
- Vitamin D3
- Where
- Israel
- Volunteers
- 47 people
- Sponsor
- Geha Mental Health Center
Diabetes, Schizophrenia
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
This is a study with an approved drug for treating type 2 diabetes, for its effects on treating glucose and lipid abnormalities in patients being treated with first or second-generation antipsychotics, and comparison of effects…
- Conditions
- Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
- Trial name
- NCT00231894
- Testing
- Pioglitazone, Life style diet group
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Refractory Schizophrenia
Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory Schizophrenia
Schizophrenia is a lifelong psychiatric disorder with a prevalence rate of 0.559% and a lifetime prevalence rate of 0.588% among Chinese adults.
- Trial name
- NCT07369401
- Testing
- Deep Brain Stimulation
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Schizophrenia
Augmenting Clozapine With Sertindole - SERCLOZ
The purpose of the study is to determine whether addition of sertindole to clozapine treatment can improve psychosis or the metabolic side-effects of clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT00345982
- Testing
- Serdolect
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Treatment Resistant Schizophrenia
Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
The proposed study will be conducted to compare the efficacy of maintenance ECT (M-ECT) vs Clozapine in treatment resistant schizophrenia (TRS) in terms of change in psychopathology measures and cerebral hemodynamics.
- Trial name
- NCT03807882
- Testing
- Bilateral M-ECT, Clozapine
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Schizoaffective Disorder
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of…
- Trial name
- HDQ (NCT00297947)
- Testing
- quetiapine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Manhattan Psychiatric Center
Schizophrenia, Schizotypal Disorder
Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis
The aim of the COPUS study is to investigate, whether it is possible to recruit and retain young people with first-episode psychosis, to an 8 week supervised High-Intensity Functional Training intervention (HIFT) (i.e.
- Conditions
- Schizophrenia, Schizotypal Disorder, First Episode Psychosis, Psychotic Disorders
- Trial name
- COPUS (NCT03409393)
- Testing
- The COPUS intervention, Usual Care (OPUS treatment)
- Where
- Denmark
- Volunteers
- 27 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Clozapine Resistant Schizophrenia
Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia
The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS.
- Trial name
- NCT06501339
- Testing
- maintenance ECT, Aripiprazole tablet
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Treatment Resistant Schizophrenia, Schizophrenia
Magnetic Seizure Therapy for Schizophrenia - Trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
- Conditions
- Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- MAST (NCT06672588)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Affective Disorder, Schizoaffective Disorder
Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder
Bipolar Disorder (BD) and Schizoaffective Disorder (SA) clients. determine if after 12 months of treatment with clozapine, the BMI changes with clients who are councelled as usual regarding weight gain while on Clozapine.
- Trial name
- NCT00683709
- Testing
- Counselling as Usual, CBT
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Schizophrenia, Treatment Resistant Disorders
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Background: schizophrenia is a debilitating mental disorder affecting about 1% of the general population. About 30% of patients will not react to current drug treatment and defined as treatment-resistant schizophrenia patients…
- Trial name
- ClozAmi (NCT01448499)
- Testing
- Clozapine, Amisulpride, Clozapine+Amisulpride
- Where
- Israel
- Sponsor
- Geha Mental Health Center
Schizophrenia, Auditory Hallucinations
Transcranial Direct Current Stimulation (tDCS) and Hallucinations in Schizophrenia
The purpose of this study is to determine whether trans Direct Current Stimulation (tDCS) is effective in the treatment of auditory hallucinations in schizophrenia.
- Trial name
- NCT00870909
- Testing
- active tDCS
- Where
- 2 sites in France, Tunisia
- Volunteers
- 46 people
- Sponsor
- Hôpital le Vinatier